Senores Pharmaceuticals , a global research-driven pharmaceutical company, has announced robust financial results for the second quarter and first half of fiscal year 2026, demonstrating significant growth across key metrics.

Q2 FY26 Highlights

Senores Pharmaceuticals reported impressive year-on-year growth for Q2 FY26:

• Revenue surged by 61% to Rs. 162.00 crores
• EBITDA increased by 113% to Rs. 50.00 crores
• Profit After Tax (PAT) grew by 131% to Rs. 30.00 crores

H1 FY26 Performance

The company's strong performance continued in the first half of FY26:

• Revenue rose by 66% to Rs. 300.00 crores
• EBITDA expanded by 88% to Rs. 84.00 crores
• PAT increased by 114% to Rs. 51.00 crores

Segment-wise Performance

Regulated Markets

• Q2 FY26 revenue stood at Rs. 107.00 crores, up 86.9% year-on-year
• EBITDA margin improved from 36% in Q1 FY26 to 44% in Q2 FY26
• H1 FY26 revenue reached Rs. 197.00 crores, growing 78.4% year-on-year with a 40% EBITDA margin

Emerging Markets

• Q2 & H1 FY26 revenue was Rs. 32.00 crores and Rs. 61.00 crores respectively
• EBITDA margins for Q2 & H1 FY26 were 6.6% and 6.2%

Branded Generics

• Witnessed significant growth, with H1 FY26 revenue increasing more than 7x year-on-year to Rs. 20.00 crores

Operational Highlights

• The company launched eight new products in Regulated Markets during Q2
• Senores currently has 32 own commercial products, 81 approved ANDA products, and 70 pipeline products in Regulated Markets
• In Emerging Markets, the company has 394 approved products and 824 products under registration across more than 40 countries

Financial Position

The company generated Rs. 31.40 crore in operating cash flow for H1 FY26, with Q1 FY26 contributing approximately Rs. 11.00 crore. This represents a significant improvement from Rs. 9.00 crore in H1 FY25, indicating enhanced cash conversion efficiency.

Management Commentary

Swapnil Shah, Managing Director of Senores Pharmaceuticals, commented on the results: "Building on the momentum from previous quarters, we delivered a strong performance in Q2 FY26, with revenues rising 61% and profit after tax growing 131% year-on-year. In the Regulated Markets, we launched eight new products during the quarter, achieving better-than-expected sales."

Shah added, "With additional launches and scale-up of existing products in the coming quarters, we expect this growth momentum in the Own Products business to continue through H2 and FY27. Margins have also strengthened, supported by a higher contribution from own products, improved operating efficiency, and inherent operating leverage."

Future Outlook

The company remains optimistic about its growth trajectory, focusing on four key pillars:

1. Expansion of the ANDA Portfolio in Regulated Markets
2. Steady Scale-up of the CDMO/CMO Segment in Regulated Markets
3. Portfolio Expansion and Profitability Improvement in Emerging Markets
4. Scale-up of Branded Generics business in India

Senores Pharmaceuticals expects to maintain and further improve its performance, with plans to achieve pan-India presence for its Branded Generics business by the end of FY26.

The company's strong Q2 and H1 FY26 results, coupled with its strategic focus on key growth areas, position Senores Pharmaceuticals well for continued success in the global pharmaceutical market.

Senores Pharmaceuticals , a global research-driven pharmaceutical company, has reported robust financial results for the second quarter and half year ended September 30, 2025, showcasing significant growth across key metrics.

Financial Highlights

Quarterly Performance

• Consolidated revenue: Rs. 162.00 crores (61% year-on-year growth)
• Profit after tax: Rs. 30.00 crores (131% year-on-year increase)

Half-Year Performance

• Consolidated revenue: Rs. 300.00 crores (66% year-on-year growth)
• Profit after tax: Rs. 51.00 crores (114% year-on-year increase)

Segment Performance

Senores Pharmaceuticals' growth was primarily driven by strong performance across various segments:

• Regulated Markets: Revenue grew by 87% year-on-year in Q2
• Branded Generics: Revenues increased more than tenfold year-on-year

Cash Flow

The company generated Rs. 31.40 crores in operating cash flow for the half year, demonstrating improved financial efficiency.

Management Appointment

The board of Senores Pharmaceuticals approved the appointment of Mr. Manohar Lalge as President-Research and Development. Key details:

• Experience: Over 25 years in pharmaceutical formulation development
• Position: Categorized as Senior Management Personnel
• Effective Date: November 6, 2025

Future Outlook

With its robust financial performance, strategic appointments, and focus on key business segments, Senores Pharmaceuticals appears well-positioned for growth in both regulated and emerging pharmaceutical markets. The strong Q2 results and addition of experienced leadership in research and development signal a positive trajectory for the company in the coming quarters.